Subscribe to Newsletter

November 2014 Issue of The Medicine Maker

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

Business & Regulation Business Practice

Big Bad Pharma?

| Charlotte Barker

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Manufacture Small Molecules

The Final Frontier?

| Stephanie Vine

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Business & Regulation Business Practice

Access All Areas

| Stephanie Vine

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Business & Regulation Drug Discovery

Battle of the Superbugs

| Stephanie Vine

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Business & Regulation

Endolysins Vs MRSA

| Stephanie Vine

What is an endolysin? We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out.

Business & Regulation Business Practice

Care to ‘Patent Dance’?

| Stephanie Vine

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

Business & Regulation Standards & Regulation

Regulators Target Ebola

| Stephanie Vine

Will FDA fast review and voucher incentives make a difference?

Discovery & Development Drug Delivery

Dosing to Circadian Rhythm

| Stephanie Vine

Could medicines be made more effective with better timing?

Business & Regulation Standards & Regulation

Making European Regulations Work

| Stephanie Vine

Pathways designed to bring medicines to market faster in Europe are not delivering the goods

Manufacture Small Molecules

Side Effects and Supercomputers

| Stephanie Vine

A group of researchers have used supercomputers to link proteins to drug side effects.

Manufacture Biosimilars

The Monoclonal Milestone

| Carsten Brockmeyer

The launch of the world’s first biosimilar monoclonal antibody was a big step forward from a regulatory and scientific standpoint.

Manufacture Small Molecules

Calculate – Don’t Estimate – Drug Development Costs

| Ayman Chit

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right?

Business & Regulation Business Practice

Sharing Data – and Knowledge

| Steve Thomas

How to use a knowledge repository that doesn’t retire or leave you for a competitor.

Discovery & Development Formulation

What About the Kids?

| Jenny Walsh

Making medicines for pediatrics adds a whole new dimension to the challenges of formulation and drug delivery

Manufacture Bioprocessing - Upstream & Downstream

Pass Me a Bottle Opener

| Jaime Marach

Can a new generation of chromatography techniques and technologies get things moving again?

Manufacture Standards & Regulation

Safety First - Sizing Up Biologics Side Effects

| Catherine Akers

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated.

Discovery & Development Small Molecules

Electrifying R&D Acceleration

| Mark R. Taylor, Susana Da Silva Torres

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings.

Business & Regulation Business Practice

Our Unholy Alliance

| Lee DesRosiers

Science and business: tenacious partners in a shaky marriage or eternally bound nonidentical twins?

Business & Regulation Small Molecules

United Science Stands

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

Discovery & Development Drug Delivery

Connecting the Dots in Drug Delivery

| Sponsored by Catalent

The days of “low-hanging fruit” in drug discovery are a thing of the past.

Other issues of 2014